1 Between February 2001 and February 2002, 946
patients were accrued.
2 From April 2001 to February 2008, 345
patients were accrued.
3 One hundred and forty-four
patients were accrued.
4 A total of 745 eligible
patients were accrued.
5 Thirty-eight
patients were accrued.
6 Between December 2001 and May 2005, 55
patients were accrued.
7 ted prematurely after 224 of a projected 400
patients were accrued.
8 tween April 1, 1995, and June 1, 1999, 1,323
patients were accrued.
9 Between July 1998 and August 2003, 36
patients were accrued;
31 were eligible.
10 Forty-five
patients were accrued;
44 patients received treatment.
11 Forty-four
patients were accrued;
60% had stage III to IV disease;
12 Thirty-five
patients were accrued,
all of whom had failed one (51%)
13 Fifty-eight evaluable
patients were accrued and randomly assigned from 2004 to
14 A total of 368
patients were accrued and received therapy.
15 Three hundred seventy-three
patients were accrued at more than 60 centers; 251 patie
16 n as the recommended dose, and 12 additional
patients were accrued at that level.
17 Ten additional
patients were accrued at the 1.3 mg/m2 bortezomib dose l
18 Sixty-seven
patients were accrued between March 1994 and April 1996.
19 A total of 380
patients were accrued between May 1990 and June 1994 int
20 Two additional
patients were accrued beyond the protocol-stipulated 46,
21 In all, 98
patients were accrued (
cohort A, 12; cohort B, 86).
22 Thirty-nine eligible
patients were accrued (
eight patients each on cohorts 1
23 Six hundred ninty-nine
patients were accrued for a SLNB with an average age 57.
24 A total of 223
patients were accrued from 1996 to 1999.
25 In all, 251
patients were accrued from 1998 to 2002.
26 rophylaxis of pain flare after radiotherapy,
patients were accrued from 23 Canadian centers from May
27 Between July 1998 and August 1999, 96
patients were accrued from 43 institutions.
28 In all, 107
patients were accrued:
gemcitabine-docetaxel plus placeb
29 Thirty-five consecutive
patients were accrued in two institutions (22 in one and
30 A total of 298
patients were accrued (
median age, 68.8 [range, 32-94] y
31 Overall, 356
patients were accrued of the targeted 1,058.
32 Thirty-seven
patients were accrued;
one patient was ineligible.
33 before the standard use of temozolomide, 191
patients were accrued onto New Approaches to Brain Tumor
34 Six hundred eighty-nine
patients were accrued over 4.5 years; 89 patients (13%)
35 Patients were accrued primarily in the community setting
36 Overall, 27 evaluable
patients were accrued;
the median number of prior therap
37 Fourteen nonimmunocompromised
patients were accrued to a chemotherapy regimen that inc
38 Forty-three and 26
patients were accrued to arms A and B, respectively.
39 Pediatric
patients were accrued to clinical trials at high levels,
40 Thirty-three eligible
patients were accrued to dose levels 1 to 8.
41 red thirty-four, 234, 241, and 235 evaluable
patients were accrued to groups 1, 2, 3, and 4, respecti
42 Three hundred eleven
patients were accrued to the Alabama Breast Cancer Proje
43 From March 2009 to December 2012, 153
patients were accrued to the study.
44 Forty-eight heavily pretreated
patients were accrued to this study.
45 Thirty-five minimally pretreated
patients were accrued using a standard two-step mechanis
46 From 255 hospitals, 22,346
patients were accrued who underwent a colon resection in
47 Ninety-seven eligible
patients were accrued with a median follow-up time of 22
48 Fifty eligible
patients were accrued with tumor-node (TN) substage conf
49 A total of 39
patients were accrued,
with 36 patients being assessable